Autoimmune Disease Series--

Psoriasis

Psoriasis is an immune-mediated skin disease that is stimulated by environmental factors and controlled by polygenic genes, and can be divided into four types: common, arthropathic, pustular and erythrodermic. Its typical manifestation is scaly erythematous plaques or plaques, which are confined to one place or widely distributed all over the body. In addition to skin damage, psoriasis may also affect the nails, joints and other parts of the body, and may even be accompanied by a variety of systemic comorbidities, such as metabolic syndrome, inflammatory bowel disease, cardiovascular disease, and mental disorders.

In recent years, significant progress has been made in drug development for psoriasis, especially in biological agents and small molecule targeted drugs. In terms of biological agents, a variety of targeted antibody drugs for psoriasis have been marketed or are in the research and development stage. These include TNF-α inhibitors, IL-12/23 inhibitors, IL-23 inhibitors, IL-17A inhibitors and IL-36 receptor inhibitors. These biologics can effectively control the symptoms of psoriasis by targeting specific inflammatory mediators. In terms of small molecule drugs, tyrosine kinase 2 (TYK2) variant inhibitors have been approved and marketed for patients with moderate to severe plaque psoriasis. In addition, JAK inhibitors, PDE4 inhibitors, and NRF2 stimulators are under development, which intervene in the pathogenesis of psoriasis through different signaling pathways.

CUSABIO provides psoriasis drug development target proteins, recombinant antibodies, ELISA kits and other products to help basic research and drug development.

Psoriasis Drug Targets Related Products

● Target Proteins

Recombinant Human Interleukin-17A (IL17A)
CSB-BP624104HU(M)

Recombinant Human Interleukin-2 (IL2)
CSB-MP011629HU

Recombinant Human Interleukin-6 (IL6)
CSB-YP011664HU

Recombinant Human Tumor necrosis factor (TNF)
CSB-YP023955HU